Earnings
Despite continued slumps in sales of its hepatitis C medications, Gilead Sciences saw a robust first quarter, with earnings up nearly 28 percent. That was good news as new Chief Executive Officer Dan O’Day marked his first full quarter with the California-based company.
The company indicated it was dropping LY2606368, prexasertib, a CHK1 drug in Phase II, and LY3023414, a PI3k/mTOR inhibitor that was also in Phase II.
Celgene, which will become part of Bristol-Myers Squibb later this year, saw positive growth in the first quarter of the year.
Pfizer closed out the first quarter of 2019 with revenues of $13.1 billion driven by a significant 36 percent global growth of Eliquis sales, a 34 percent increase in Xeljanz revenue and a 25 percent increase in sales of Ibrance, the company announced this morning.
AstraZeneca reported first-quarter financials, with Product Sales growing 10% (14% at CER) to $5.465 billion. What is more startling, and completely in accordance with the company’s stated goals, Global Oncology sales increased by 54%.
Earlier this week, Biogen reported out its first-quarter financial results, showing an 11% increase in revenues, hitting $3.5 billion. But in light of the company’s announcement in late March that it was dropping development of aducanumab for Alzheimer’s, analysts are speculating on what the company needs to do to stay profitable.
Galapagos NV presents financial results and highlights the key events for the first quarter of 2019.
Conference call to be held today, 25 April 2019, 3:00pm CET/2:00pm BST
Preparations for Upcoming Clinical Data in the MERECA and GIST Studies and First Patient Treated in the ILIAD Study
ADOCIA announces its financial results, including revenue and cash position, for the quarter ended March 31st, 2019.
PRESS RELEASES